Type 2 Gaucher disease: 15 new cases and review of the literature.
about
Imiglucerase in the treatment of Gaucher disease: a history and perspectiveThe clinical management of Type 2 Gaucher diseaseImiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapyA Review of Gaucher Disease Pathophysiology, Clinical Presentation and TreatmentsMurine models of acute neuronopathic Gaucher disease.The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients.Neonatal cholestasis as initial manifestation of type 2 Gaucher disease: a continuum in the spectrum of early onset Gaucher disease.Hemophagocytic lymphohistiocytosis triggered by Gaucher disease in a preterm neonate.Bone events and evolution of biologic markers in Gaucher disease before and during treatment.ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.Gaucher disease and its treatment options.Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.Hemophagocytic lymphohistiocytosis syndrome associated with Gaucher disease type 2Skin ultrastructural findings in type 2 Gaucher disease: diagnostic implications.Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology.Type 2 Gaucher disease occurs in Ashkenazi Jews but is surprisingly rare.Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease.Convection-enhanced delivery for the treatment of pediatric neurologic disorders.Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.Trismus in the paediatric population.The clinical spectrum of inherited diseases involved in the synthesis and remodeling of complex lipids. A tentative overview.Splenomegaly as a primary manifestation of Gaucher disease in a young adult woman.Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.Unusual manifestations and unusual mimics of adult onset Still's disease.Functional antibody deficiency in a patient with type I Gaucher disease.Congenital Gaucher disease with nonimmune hydrops/erythroblastosis, infantile arterial calcification, and neonatal hepatitis/fibrosis. Clinicopathologic report with enzymatic and genetic analysis.Oxidative stress, trace elements, and circulating microparticles in patients with Gaucher disease before and after enzyme replacement therapy.Type II Gaucher disease manifesting as haemophagocytic lymphohistiocytosis.Gaucher Disease Type 2 Presenting with Collodion Membrane and Blueberry Muffin Lesions.Gaucher diseasePhenotypic variability of prenatally presenting Gaucher's disease
P2860
Q24631426-9C797ED0-E1F3-430A-94FD-BEB995186AF7Q26825082-C4CC04A2-CE9F-42F3-8ED2-A541CF0F6685Q28067032-10F465C6-2DCE-42C7-8FAD-2070D5B7F201Q30235844-8CC6E299-7C7C-4944-97C7-A64D15DF24E7Q30480646-64406291-5C49-4787-8122-37FF4DAEF097Q33403714-22DD614E-7B61-480E-81CF-2747435C6175Q33406021-ED81FB84-C982-49B6-9951-6245A4A50033Q33437420-1E2F8483-06CF-406C-A844-4E52FCA4ED2FQ34153094-023B76A5-4CB1-46EA-98F0-7C30A0D35C78Q34273177-94AF31F1-E9F6-4E2E-948B-BE6FD254D444Q34386658-24A76A73-26FA-4CB9-BDA1-133CE111B6E6Q34479337-E569698E-82FC-4E4A-8157-973ACA1872C4Q34868504-C5F29D59-1EA3-4304-B75D-53B95875F9C4Q35573474-F84D1455-6481-468B-AC53-E45C7A549347Q35589803-A00C6F16-F990-4DD1-83A2-B4FE03632D83Q35969501-58CC9508-7E01-4E6C-ADEF-3AF908FAEDC2Q36123828-8121BCF4-789F-47C4-A027-9B06BF11C714Q36907531-A4A2E412-43CD-4DE9-BBBD-B7F55BAC1915Q37354438-73ECB840-4133-42CD-97E5-8F818CFE360BQ38269349-5CA43109-17E7-4597-9E3E-6000E4EE692CQ38270108-95CD2575-31F3-47A9-81CD-F65D79E92D18Q38303341-4079F8B6-50A6-4F5F-883E-96088B420BE6Q39510850-F6F4254F-5A97-4160-83E0-7CB694348521Q41887691-6428E2F2-F3AE-4C5D-871E-BED3868C9DC3Q42240996-FBB23419-DC5C-4A0D-BFD1-3372B9D20FDFQ44881229-AC35AFAB-7A5E-414D-BE57-2591C90D489CQ46012526-2C09F72B-2053-47CC-983D-8B723F6EA216Q46241928-B5FCD7B4-A5FC-4FDC-A605-1ABB9A525D0FQ51780414-3124DB39-BD11-40EE-963C-C1357C6E7ECEQ53251392-00562F9D-3EF3-4A2D-8DD5-08799C13E204Q56338451-BBADA6C3-5ACE-409B-820B-315E75195254Q58350879-E9F51072-C1EC-4D6C-BDB6-21EE91F3972D
P2860
Type 2 Gaucher disease: 15 new cases and review of the literature.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Type 2 Gaucher disease: 15 new cases and review of the literature.
@ast
Type 2 Gaucher disease: 15 new cases and review of the literature.
@en
type
label
Type 2 Gaucher disease: 15 new cases and review of the literature.
@ast
Type 2 Gaucher disease: 15 new cases and review of the literature.
@en
prefLabel
Type 2 Gaucher disease: 15 new cases and review of the literature.
@ast
Type 2 Gaucher disease: 15 new cases and review of the literature.
@en
P2093
P1476
Type 2 Gaucher disease: 15 new cases and review of the literature.
@en
P2093
Cyril Mignot
Diana Doummar
French Type 2 Gaucher Disease Study Group
Irène Maire
Thierry Billette De Villemeur
P356
10.1016/J.BRAINDEV.2005.04.005
P577
2006-01-01T00:00:00Z